SI-Bone price target lowered to $16 from $18 at Truist

Truist lowered the firm’s price target on SI-Bone to $16 from $18 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get “a pass” from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that it sees a modest Q3 revenue beat while noting Si-Bone’s operational catalysts that include “TORQ TNT for pelvic fracture launch” and achieving positive EBITDA in Q4 that generally create a good setup heading into the print.